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Transcriptional control: Tat cofactors and transcriptional elongation
Krassimir Yankulov* and David Bentley†
HIV-1 gene expression requires the transactivator Tat,
which stimulates viral transcript elongation. Recent
results show that two cellular cyclin-dependent kinases,
which phosphorylate the carboxy-terminal domain of
the RNA polymerase II large subunit, contact Tat and
contribute to the control of transcriptional elongation.
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The transcriptional activator protein Tat of human
immundeficiency virus-1 (HIV-1) enhances synthesis of
viral RNA by a very unusual mechanism. Firstly, unlike
other viral and cellular activators that recognise specific
sequence elements in promoter DNA, Tat recognises a
hairpin loop structure, known as TAR, near the 5′ end of
the viral RNA. And secondly, in contrast to all other acti-
vators, Tat does not have much effect on the frequency of
RNA chain initiation. Rather, the main effect of Tat is to
stimulate RNA polymerase II processivity, causing an
increase in the fraction of transcripts that extend all the
way to the 3′ end of the provirus. Without Tat, most viral
transcripts terminate prematurely at many positions
throughout the 9.5 kilobase proviral genome. 
How can Tat, which binds to the 5′ proximal region of the
RNA, stimulate elongation by polymerase II through distal
arrest sites? Recently, important clues towards a solution
of this puzzle have been discovered. These exciting find-
ings draw together three previously disparate strands of
evidence: a species-specific cofactor for Tat encoded by a
gene that maps to human chromosome 12; a protein kinase
that binds to Tat and phosphorylates the carboxy-terminal
heptad-repeat domain (CTD) of the RNA polymerase II
large subunit; and a ‘positive transcription elongation
factor’ (P-TEFb) purified from Drosophila cells.
P-TEFb was identified on the basis of its ability to
stimulate the production of long RNAs in vitro when added
to polymerase II transcription complexes shortly after initia-
tion [1]. This activity of P-TEFb is sensitive to the protein
kinase inhibitor dichloro-ribofuranosyl benzimidazole
(DRB), which selectively blocks synthesis of long RNAs,
such as Tat-activated HIV-1 transcripts, without affecting
the production of short RNAs such as those produced in the
absence of Tat [2]. Price’s group sequenced two subunits of
P-TEFb and found that they correspond to a previously dis-
covered cyclin-dependent kinase, Cdk9, and a new partner,
cyclin T [3,4]. The same cyclin-dependent kinase was iden-
tified independently as a kinase that bound in vitro to the
activation domain of Tat and phosphorylated the RNA
polymerase II CTD [5]. Cyclin T was also identified by Wei
et al. [6] as a protein that bound to a Tat affinity resin. 
The functional significance of Cdk9–cyclin T was
demonstrated by its immunodepletion from transcription
extracts, which was found to inhibit activation by Tat as
well as basal transcription [3,6,7]. Other accessory proteins
are associated with Cdk9–cyclin T, including Tat-SF1
(Q. Zhou, personal communication), a previously reported
cellular cofactor for Tat [8]. The importance of P-TEFb
was further supported by the results of a screen through
100,000 compounds for inhibitors of Tat function [7].
Among the compounds that emerged from this screen, a
compelling correlation was found between their ability to
inhibit Tat activity, on the one hand, and P-TEFb kinase
activity, on the other. 
The interaction of P-TEFb with Tat has a fascinating effect
on recognition of TAR. Pure Tat binds exclusively to
residues in the bulge of the TAR hairpin structure, but
residues in the loop are critical for activation of transcription
by Tat. Elegant experiments by Wei et al. [6] have now pro-
vided a solution to this paradox. These workers discovered
that cyclin T binds directly to Tat, that the cyclin T–Tat
complex binds TAR with higher affinity than Tat alone, and
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Cyclin T binds directly to the Tat activation domain, conferring tight
binding to TAR RNA and recognition of the loop [6].
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that cyclin T confers recognition of the loop as well as the
bulge (Figure 1). HIV-1 appears to have evolved a cunning
scheme in which it ‘cooperates’ with a host-cell factor, cyclin
T, that simultaneously enhances Tat binding to TAR and
recruits the P-TEFb kinase that stimulates the processivity
of viral transcription. Moreover, cyclin T fulfills the criteria
for the species-specific host-cell factor: the human cyclin T
gene maps to chromosome 12 and its over-expression in
rodent cells is sufficient to permit Tat activation [6].
P-TEFb is not the only protein kinase that binds to the
Tat activation domain. The multi-subunit general
transcription factor TFIIH, which has its own tripartite
protein kinase, Cdk7–cyclin H–MAT1, binds to the same
domain of Tat [9–12]. Like P-TEFb, TFIIH kinase
phosphorylates the polymerase II CTD. Specific inhibi-
tion of Cdk7 by a pseudosubstrate peptide was found to
reduce polymerase II processivity in the presence of Tat,
suggesting that this kinase is required in addition to P-
TEFb for Tat function [11]. TFIIH cannot substitute for
P-TEFb in stimulating elongation in vitro, so these factors
perform non-redundant functions [13].
RNA polymerase II is recruited to promoters in its hypo-
phosphorylated IIA isoform, and then gets converted to
the II0 form by multiple phosphorylations of the large
subunit’s CTD, comprising a heptad sequence (consensus
YSPTSPS) which is repeated 52 times. The idea that
polymerase II elongation is regulated by CTD phosphory-
lation has been popular for several years, and is substan-
tially strengthened by the new evidence for interaction
between Tat and CTD kinases. Both TFIIH and P-TEFb
can convert polymerase IIA to the II0 isoform in vitro, and
both are sensitive to the elongation inhibitor DRB, but
there are also important differences between them. 
Although Tat stimulates phosphorylation of the CTD by
TFIIH [9–11], there is no evidence that it also enhances
P-TEFb activity. Furthermore, TFIIH and P-TEFb act at
two different times in the transcription reaction. TFIIH is
a component of the pre-initiation complex that assembles
on the promoter. It acts during initiation and promoter
clearance, and is released when the RNA chain is 30–50
bases long [14]. In contrast, P-TEFb is not part of the pre-
initiation complex. It works later in the reaction, during a
window between when the polymerase clears the pro-
moter — with a nascent RNA chain of about 15 bases —
and when the transcript reaches about 500 bases [15].
These findings suggest a two-stage model for CTD
phosphorylation, in which TFIIH acts first during the
transition from initiation to elongation, and P-TEFb then
acts as the transcript elongates through the first few
hundred bases. The slow initial kinetics of CTD phospho-
rylation by P-TEFb in vitro [13] suggest that this kinase’s
activity might be enhanced if the substrate is first phos-
phorylated by TFIIH. Tat may be so effective at stimulat-
ing elongation because it integrates the two stages of
CTD phosphorylation by contacting both TFIIH and P-
TEFb (Figure 2). It remains to be determined whether
the association of Tat with TFIIH and P-TEFb is sequen-
tial or simultaneous. In either case, it is possible that these
two kinases communicate by phosphorylating one
another, possibly under the influence of Tat (see
Figure 2). The recent advances thus suggest a model in
which Tat bound to TAR installs two kinases, which
together make an efficient CTD phosphorylation machine
that launches highly processive polymerase II complexes.
The breakthroughs in understanding how Tat works have
important implications for the mechanism of activation by
other viral and cellular transcription factors. Tat is not
alone in its ability to stimulate polymerase II processivity,
although it appears to be unique in so far as it almost exclu-
sively affects this step in the transcription cycle. Other
more conventional activators that stimulate elongation as
well as initiation include herpes simplex virus VP16 and
adenovirus E1a, and the cellular proteins p53 and E2F. All
of these factors, like Tat, bind to TFIIH [12]. Whether 
P-TEFb interacts directly or indirectly with activators
others than Tat will no doubt shortly be resolved, though it
is obvious that P-TEFb function is not limited to HIV-1
transcription. P-TEFb was, after all, originally isolated as a
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Figure 2
(a) A model for the two-stage phosphorylation of RNA polymerase CTD,
first by TFIIH and then by Cdk9–cyclin T (P-TEFb). (b) Tat binding to 
P-TEFb and TFIIH may enhance the efficiency of CTD phosphorylation,
launching highly processive polymerase II elongation complexes.
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factor that stimulates the elongation of transcripts from
Drosophila promoters. Moreover, Cdk9–cyclin T over-
expression in mammalian cells stimulates Tat-indepen-
dent gene expression from a cytomegalovirus promoter [4].
Exactly how P-TEFb is brought into play in the absence of
Tat is still not known.
Despite the large body of evidence indicating that CTD
phosphorylation positively affects the processivity of tran-
scription, the underlying mechanism is completely
unknown. CTD phosphorylation could work in various
ways — it might influence the intrinsic catalytic properties
of polymerase II, recruit elongation factors, or counteract
inhibitors of elongation such as the recently discovered
‘DRB sensitivity inducing factor’ (DSIF) [16]. CTD
dephosphorylation might also have an important regula-
tory function, and in this regard it is intriguing that a
recently identified CTD phosphatase binds directly to the
elongation factor TFIIF [17]. 
How does Tat bound to the 5′ end of HIV-1 RNA act at a
distance to prevent premature termination of transcription
throughout the provirus? It is possible that the pattern of
CTD phosphorylation set up by Tat, TFIIH and P-TEFb
at the beginning of a round of HIV-1 transcription is stable
enough to maintain high processivity until the polymerase
reaches the 3′ end of the provirus. Alternatively, it may be
necessary to maintain the phosphorylation state of the
elongating polymerase constantly, perhaps by hit-and-run
binding of P-TEFb. In this regard, it is interesting to note
that Tat associates with polymerase II complexes [18] and
may actually travel as a passenger with the enzyme during
transcript elongation [19].
CTD phosphorylation has been implicated not only in
controlling elongation of nascent transcripts in response to
activators, but also in co-transcriptional processing of those
transcripts. The 5′ ends of eukaryotic pre-mRNAs are
‘capped’ with a structure that is important for their
subsequent processing, transport and translation: this
capping is dependent on the polymerase II CTD and
involves recruitment of the capping enzymes specifically
to the phosphorylated CTD [20]. It is also possible that
association of splicing and polyadenylation factors with an
‘mRNA factory’ complex is influenced by CTD phospho-
rylation [21]. CTD phosphorylation under the direction of
Tat and perhaps other transcription factors may therefore
influence multiple post-initiation events in mRNA syn-
thesis. High polymerase II processivity in response to
CTD phosphorylation could be just one manifestation of a
commitment by the gene expression machinery to synthe-
size a full-length and completely processed mRNA. 
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